ArticleCancers2022
Fertility Sparing Surgery and Borderline Ovarian Tumours.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- STL-DeepBDC: A Robust Few-Shot Learning Framework for Multiclass Ovarian Tumor Classification in Ultrasound Outperforms Conventional Transfer Learning.Cancer medicine · 2026Article
- Article
- How to integrate O-RADS MRI scores with clinical and imaging criteria to predict histopathological subtypes.European radiology · 2026Article
- The Oncological Follow-Up of Fertility Sparing Surgery for Mucinous Borderline Ovarian Tumours: A Retrospective Cohort Study.Cancers · 2025Article
- Use of intraoperative ultrasound in resection of early-stage borderline ovarian tumors:Gynecologic oncology reports · 2025Article
- Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Oncofertility outcomes after fertility-sparing surgery in infertile BOT patients: results of a large retrospective study on controlled ovarian stimulation.Frontiers in oncology · 2025Article
- Oncofertility and Fertility Preservation for Women with Gynecological Malignancies: Where Do We Stand Today?Biomolecules · 2024Review
- Navigating Fertility Preservation Options in Gynecological Cancers: A Comprehensive Review.Cancers · 2024Review
- Article
- The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age.Frontiers in surgery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine the oncological outcomes following fertility-sparing surgery (FSS) for the management of Borderline Ovarian Tumours (BOTs). A retrospective analysis of participants diagnosed with BOTs between January 2004 and December 2020 at the West London Gynaecological Oncology Centre was conducted. A total of 172 women were diagnosed; 52.3% (90/172) underwent FSS and 47.7% (82/172) non-FSS. The overall recurrence rate of disease was 16.9% (29/172), of which 79.3% (23/29) presented as the recurrence of serous or sero-mucinous BOTs and 20.7% (6/29) as low-grade serous carcinoma (LGSC). In the FSS group, the recurrence rate of BOTs was 25.6% (23/90) presenting a median 44.0 (interquartile range (IQR) 41.5) months, of which there were no episodes of recurrence presenting as LGSC reported. In the non-FSS group, all recurrences of disease presented as LGSC, with a rate of 7.7% (6/78), following a median of 47.5 months (IQR 47.8). A significant difference between the type of surgery performed (FSS v Non-FSS) and the association with recurrence of BOT was observed (Pearson Chi-Square:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.